Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Citi Pharmaceuticals Friatroy

This article was originally published in The Tan Sheet

Executive Summary

Citi Pharmaceuticals Friatroy: Herbal product is being distributed with claims for, among other things, tumor mass reduction, decrease in tumor markets, decrease in asthenia (weakness or loss of strength), reduction in pain and as a diuretic, FDA states in a Jan. 16 warning letter to the Miami-based firm. Citi published ads for conferences/seminars that state that "doctors will speak about Friatroy for the treatment of cancer and HIV/AIDS," FDA notes, making the product an unapproved drug for those diseases...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086661

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel